Plethico Pharmaceuticals Peer Comparison

NSE: PLETHICO | BSE: 532739

₹7.94

₹-0.41 (-4.91%)

As on 13-Jun-2016IST

Market cap

₹27 Cr

Revenue (TTM)

₹765 Cr

P/E Ratio

P/B Ratio

Div. Yield

0 %

Edit

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	27	31,863	30,485	28,611	27,284
Revenue (₹ Cr)	765	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-277.72	414.00	288.22	-371.81	387.35
Net Margin (%)	-36.30	11.23	14.79	-3.93	26.01
RoE (%)	-3.05	8.38	29.77	-3.85	25.18
Price to Earnings	--	77.90	105.77	--	70.64
Price-To-Book	0.02	6.33	22.71	3.57	15.78

Income Statement (₹ Cr)

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	1,631.54	4,350.50	34.80	--	33.90
Total Income	1,664.40	4,375.84	34.80	--	34.61
Total Expenditure	1,470.36	2,996.79	25.65	--	30.42
EBITDA	161.19	1,353.71	9.15	--	3.48
Depreciation	17.73	115.07	2.71	--	1.05
EBIT	143.46	1,238.64	6.44	--	2.42
Interest	67.04	269.02	2.51	--	1.10
Other Income	32.86	25.34	0.42	--	0.71
Exceptional Items	-63.00	-473.77	--	--	--
Profit before Tax	109.28	521.19	3.93	--	2.03
Provision for Tax	7.79	221.74	1.40	--	0.68
Profit after Tax	101.49	299.45	2.52	--	1.35

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	1,366.97	1,471.02	37.49	--	6.11
Minority Interest	--	--	--	--	--
Non-Current Liabilities	259.47	2,891.88	5.39	--	0.04
Current Liabilities	1,096.26	1,890.94	24.92	--	15.82
Total Liabilities	2,731.65	6,253.84	67.79	--	22.09

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	1,021.84	3,772.33	47.64	--	5.51
Current Assets	1,700.86	2,481.51	20.15	--	16.45
Total Assets	2,731.65	6,253.84	67.79	--	22.09
Total Debt*	1,187.23	3,492.50	19.14	--	6.41
Net Current Assets	604.59	590.57	-4.76	--	0.63
Contingent Liabilities	234.37	46.91	0.71	--	--

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-61.01	1,343.83	5.07	--	--
Cash Flow from Investing Activities	7.52	-305.45	-4.60	--	--
Cash from Financing Activities	-40.51	-826.56	-0.83	--	--
Net Cash Inflow / Outflow	-94.00	211.82	-0.36	--	0.00

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	7.07	16.20	12.09	--	25.61
ROE (%)	7.48	66.74	14.65	--	24.87
ROA (%)	3.85	4.97	4.06	--	6.42
EBIT Margin (%)	11.89	31.70	26.29	--	12.34
Net Margin (%)	6.10	6.84	7.25	--	3.90
Cash Profit Margin (%)	7.31	9.52	15.04	--	6.56

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	5.17	15.97	65.29	--	21.86
EBIT Growth (%)	-35.45	29.05	42.04	--	27.63
Net Profit Growth (%)	-1.38	212.90	6.25	--	7.55
EPS Growth (%)	-1.38	278.36	6.25	--	7.55
Book Value Growth (%)	1.64	253.45	15.81	--	28.51

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	10.26	17.64	0.00	--	0.00
Price / Book Value	0.76	9.37	0.00	--	0.00
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	11.32	7.33	4.36	--	1.71
Market Cap (₹ Cr)	1,041.09	6,555.46	0.00	--	0.00

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.87	2.39	0.51	--	1.05
Short term debt to equity ratio	0.16	0.18	0.21	--	0.88
Current Ratio	1.55	1.31	0.81	--	1.04
Quick Ratio	1.38	0.84	0.77	--	0.66
Interest Coverage	2.63	2.94	2.57	--	2.86

	Plethico Pharmaceuticals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	75.01	17.44	42.51	--	24.27
Asset Turnover	0.62	0.72	0.56	--	1.74
Receivable days	245.46	57.17	120.33	--	81.45
Inventory Days	41.56	67.16	9.04	--	45.36
Payable days	23.59	116.25	535.25	--	134.63
Cash Conversion Cycle	263.43	8.07	-393.94	--	-7.82

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.